DK1755647T3 - Behandling af amyotrofisk lateral sklerose - Google Patents

Behandling af amyotrofisk lateral sklerose

Info

Publication number
DK1755647T3
DK1755647T3 DK05747975.0T DK05747975T DK1755647T3 DK 1755647 T3 DK1755647 T3 DK 1755647T3 DK 05747975 T DK05747975 T DK 05747975T DK 1755647 T3 DK1755647 T3 DK 1755647T3
Authority
DK
Denmark
Prior art keywords
treatment
lateral sclerosis
amyotrophic lateral
relates
als
Prior art date
Application number
DK05747975.0T
Other languages
English (en)
Inventor
Peter Carmeliet
Original Assignee
Vib Vzw
Life Sciences Res Partners Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vib Vzw, Life Sciences Res Partners Vzw filed Critical Vib Vzw
Application granted granted Critical
Publication of DK1755647T3 publication Critical patent/DK1755647T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Automatic Cycles, And Cycles In General (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK05747975.0T 2004-05-27 2005-05-27 Behandling af amyotrofisk lateral sklerose DK1755647T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04102334 2004-05-27
PCT/EP2005/052430 WO2005117946A1 (en) 2004-05-27 2005-05-27 Treatment of amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
DK1755647T3 true DK1755647T3 (da) 2010-10-11

Family

ID=34968798

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05747975.0T DK1755647T3 (da) 2004-05-27 2005-05-27 Behandling af amyotrofisk lateral sklerose

Country Status (17)

Country Link
US (2) US7687463B2 (da)
EP (1) EP1755647B1 (da)
JP (2) JP5537770B2 (da)
AT (1) ATE478678T1 (da)
AU (1) AU2005249234B2 (da)
CA (1) CA2568158A1 (da)
CY (1) CY1111654T1 (da)
DE (1) DE602005023155D1 (da)
DK (1) DK1755647T3 (da)
ES (1) ES2351804T3 (da)
HR (1) HRP20100555T1 (da)
ME (1) ME01870B (da)
PL (1) PL1755647T3 (da)
PT (1) PT1755647E (da)
RS (1) RS51481B (da)
SI (1) SI1755647T1 (da)
WO (1) WO2005117946A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2551160T3 (es) * 2000-04-12 2015-11-16 Vib Vzw Uso de VEGF y homólogos para tratar trastornos neurológicos
ES2351804T3 (es) * 2004-05-27 2011-02-10 Vib, Vzw Tratamiento de esclerosis lateral amiotrófica.
US20130274235A1 (en) * 2010-10-08 2013-10-17 The General Hospital Corporation Treatment of motor neuron disease
WO2014025761A1 (en) * 2012-08-07 2014-02-13 Children's Medical Center Corporation Methods to treat neurodegenerative diseases
US20140155816A1 (en) * 2012-10-09 2014-06-05 Eu Sol Biotech Co., Ltd. Method for treating brain injury or stroke
CN105960453A (zh) * 2013-10-01 2016-09-21 卡迪马干细胞有限公司 从人多能干细胞定向分化星形胶质细胞用于肌萎缩侧索硬化(als)的治疗和药物筛选
KR20230138815A (ko) * 2022-03-24 2023-10-05 주식회사 아이엔테라퓨틱스 인비보 패치 클램프 기법을 이용한 전기생리학적 약효 평가법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
SK95599A3 (en) 1997-01-17 2000-05-16 Rhone Poulenc Rorer Sa Adenoviral-vector-mediated gene transfer into medullary motor neurons
AU3072099A (en) 1998-03-13 1999-09-27 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
DK1064382T3 (da) 1998-03-17 2008-12-08 Genentech Inc Homologe polypeptider til VEGF og BMP1
GB2358020A (en) 1998-09-23 2001-07-11 Oxford Biomedica Ltd Polynucleotide constructs and uses thereof
US7125856B1 (en) 1999-04-15 2006-10-24 St. Elizabeth's Medical Center Of Boston, Inc. Angiogenic growth factors for treatment of peripheral neuropathy
EP1169052B1 (en) 1999-04-15 2005-07-20 Caritas St. Elizabeth's Medical Center of Boston, Inc. Vegf angiogenic growth factors for treatment of peripheral neuropathy
ES2551160T3 (es) 2000-04-12 2015-11-16 Vib Vzw Uso de VEGF y homólogos para tratar trastornos neurológicos
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
JP2006502240A (ja) * 2002-10-04 2006-01-19 オックスフォード バイオメディカ （ユーケー） リミテッド ベクター系
ES2351804T3 (es) * 2004-05-27 2011-02-10 Vib, Vzw Tratamiento de esclerosis lateral amiotrófica.

Also Published As

Publication number Publication date
EP1755647B1 (en) 2010-08-25
WO2005117946A1 (en) 2005-12-15
US7687463B2 (en) 2010-03-30
JP5537770B2 (ja) 2014-07-02
AU2005249234A1 (en) 2005-12-15
ATE478678T1 (de) 2010-09-15
DE602005023155D1 (de) 2010-10-07
US20080279906A1 (en) 2008-11-13
US20100152116A1 (en) 2010-06-17
CA2568158A1 (en) 2005-12-15
ES2351804T3 (es) 2011-02-10
US7863246B2 (en) 2011-01-04
JP2012111774A (ja) 2012-06-14
EP1755647A1 (en) 2007-02-28
RS51481B (en) 2011-04-30
SI1755647T1 (sl) 2011-01-31
JP2008500312A (ja) 2008-01-10
AU2005249234B2 (en) 2010-08-05
PL1755647T3 (pl) 2011-01-31
CY1111654T1 (el) 2015-10-07
ME01870B (me) 2011-04-30
PT1755647E (pt) 2010-09-29
HRP20100555T1 (hr) 2011-01-31

Similar Documents

Publication Publication Date Title
DK1755647T3 (da) Behandling af amyotrofisk lateral sklerose
DOP2015000043A (es) Agentes inductores de apoptosis para el tratamiento de cáncer y enfermedades inmunes y autoinmunes
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE537709T1 (de) Verfahren zur verringerung des exkrementgeruchs von heimtieren
ATE540949T1 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
ATE519488T1 (de) Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
ATE482709T1 (de) Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen
DE502006008804D1 (de) Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen
ATE398398T1 (de) Nahrungsmittelzusatz
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
ATE469657T1 (de) Immunstimulatorische kombination zur vorbeugung und behandlung von hepatitis c
SV2006002296A (es) Tratamiento de mastitis ref. bhc041335-sv
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit
MY147152A (en) Anti-foot-and-mouth disease virus agent for animal belonging to family suidae or sheep, and method for prevention or treatment of foot-and-mouth disease in animal belonging to family suidae or sheep
ATE482706T1 (de) Behandlung bakterieller erkrankungen der atmungsorgane durch lokale applikation von fluorchinolonen
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины
FR2905600B1 (fr) Traitement des vertiges par l'acetyl-l-leucine.
FR2867026B1 (fr) Composition phytosanitaire destinee au traitement antifongique des cultures.
ATE433983T1 (de) Thiadibenzoazulenderivate zur behandlung von entzündlichen erkrankungen
ATE425755T1 (de) 4-aminophenyl-morpholinon-derivate zur behandlung von hepatitis c